(BMRN) BioMarin Pharmaceutical Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BMRN) BioMarin Pharmaceutical Inc. Complete Analysis Pack
See the Bigger Picture
This BioMarin Pharmaceutical Inc. BCG Matrix is a ready-made strategic tool used to assess the company’s products or business units across the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Voxzogo, first-in-class achondroplasia therapy
Voxzogo is BioMarin Pharmaceutical Inc.'s main growth engine heading into end-2025, with achondroplasia affecting roughly 1 in 15,000 to 1 in 25,000 births and still underdiagnosed in many markets. It was the first approved treatment for achondroplasia, giving BioMarin strong first-mover control as the patient pool expands. As diagnosis, reimbursement, and access improve, Voxzogo should keep widening its reach and supporting BioMarin's top line.
Voxzogo, global rollout and label expansion
Voxzogo is BioMarin Pharmaceutical Inc.'s clearest Star: 2024 revenue reached about $618 million, up 9% year over year, and the brand kept scaling beyond the U.S. It is approved in major markets including the U.S., EU, Japan, and China, with more countries and treated patients supporting the growth case. Ongoing label expansion in younger and broader achondroplasia groups should keep demand rising.
Palynziq, severe PKU franchise
Palynziq stayed a Star in 2025, with BioMarin keeping it as a key growth drug in severe PKU. The franchise targets a narrow but expandable adult PKU pool, and uptake keeps rising as more patients move into specialty treatment. In 2025, its growing use helped BioMarin deepen rare-disease sales momentum.
Palynziq, only commercial PAL enzyme therapy
Palynziq is BioMarin Pharmaceutical Inc.’s only commercial phenylalanine ammonia lyase (PAL) enzyme therapy, and its pegvaliase mechanism gives it a clear edge in phenylketonuria, a rare disease affecting about 1 in 10,000 to 1 in 15,000 births. That differentiation supports share in a niche with limited direct competition, and the brand can stay in Star territory if 2025/2026 patient starts and long-term persistence remain strong.
- Only commercial PAL enzyme therapy
- Rare-disease niche, limited competition
- Depends on starts and persistence
Rare-disease launch platform, 2 growth brands
BioMarin Pharmaceutical Inc.’s near-term growth is centered on Voxzogo and Palynziq, its two clearest orphan-market engines. In 2024, Voxzogo revenue rose to about $1.1 billion and Palynziq to roughly $0.4 billion, showing strong share in rare-disease niches with more room to penetrate than mass markets. Together, they are BioMarin Pharmaceutical Inc.’s best fit for the BCG “Stars” box: high growth, high share, and still expanding.
- Voxzogo: largest growth driver
- Palynziq: smaller but durable
- Both target orphan markets
- Penetration still has runway
BioMarin’s Rare-Disease Stars Keep Shining
Voxzogo and Palynziq are BioMarin Pharmaceutical Inc.’s Stars: both sit in rare-disease markets with strong growth and clear pricing power. Voxzogo led with about $1.1 billion in 2024 revenue, while Palynziq added about $0.4 billion, and both still have room to expand as diagnosis and access improve in 2025/2026.
| Product | 2024 Revenue | BCG Role |
|---|---|---|
| Voxzogo | $1.1 billion | Star |
| Palynziq | $0.4 billion | Star |
What is included in the product
Detailed Word Document
BioMarin’s BCG Matrix maps its drugs into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
BioMarin Pharmaceutical Inc. BCG Matrix for quick quadrant clarity and easier portfolio decisions.
Reference Sources
Provides a credible source trail for BioMarin’s key assumptions, helping users verify claims fast and make better decisions.
Cash Cows
Vimizim, MPS IVA enzyme replacement
Vimizim, approved in 2014 for MPS IVA, is a long-established orphan enzyme therapy with durable demand and a strong niche position. In BioMarin Pharmaceutical Inc.'s 2024 results, it remained part of a portfolio that generated about $2.4 billion in total revenue, supporting steady cash flow. The market is mature and low-growth, but Vimizim still fits the Cash Cows bucket.
Naglazyme, MPS VI franchise
Naglazyme has been commercial since 2005, so it fits BioMarin Pharmaceutical Inc.'s cash cow profile: mature, steady, and highly focused on a tiny MPS VI market. The franchise keeps recurring revenue with little growth, but its rare-disease position stays structurally strong because treatment options are limited. It is old money, not growth money.
Brineura, CLN2 Batten disease
Brineura targets CLN2 Batten disease in children 3 years and older, with infusions every 2 weeks and few direct substitutes. The patient pool is ultra-small and the market is stable, not fast growing. That makes Brineura a Cash Cow for BioMarin Pharmaceutical Inc., generating recurring cash more than expansion.
Aldurazyme, MPS I legacy biologic
Aldurazyme remains a mature, low-growth asset in BioMarin Pharmaceutical Inc.'s portfolio. As an MPS I legacy biologic, it still brings in revenue from a tiny, stable patient base, but the runway is capped because new demand is limited and the franchise is long past its high-growth phase.
- Older, well-known rare-disease therapy
- Stable demand, weak growth upside
- Still cash-generative for BioMarin Pharmaceutical Inc.
- Fits the cash cow box in BCG terms
Kuvan, residual PKU revenue base
Kuvan is a legacy PKU asset that still throws off cash, even as generic sapropterin pressure keeps sales in decline. PKU affects roughly 1 in 25,000 to 1 in 50,000 births, so the core market is stable, not fast-growing. BioMarin can harvest the remaining revenue base without heavy reinvestment.
- Legacy asset
- Cash flow still positive
- Growth now limited
- Best use is harvest, not expansion
BioMarin’s Cash Cows Keep Revenue Flowing
BioMarin Pharmaceutical Inc.'s Cash Cows are its mature rare-disease brands: Vimizim, Naglazyme, Brineura, Aldurazyme, and Kuvan. In 2024, BioMarin Pharmaceutical Inc. generated about $2.4 billion in revenue, and these franchises still deliver steady cash from small, stable patient pools. Growth is limited, but the installed base keeps revenue recurring.
| Asset | Cash Cow signal |
|---|---|
| Vimizim | Durable niche demand |
| Naglazyme | Mature, steady cash |
| Brineura | Ultra-small stable market |
Full Version Awaits
BioMarin Pharmaceutical Inc. Reference Sources
You’re previewing the exact BioMarin Pharmaceutical Inc. BCG Matrix report you’ll receive after purchase. The file is fully formatted, with no watermarks or demo content. What you see here is the same document delivered for immediate use in analysis, presentations, or strategic planning.
Dogs
Kuvan, generic erosion and declining share
Kuvan has lost strategic weight as BioMarin Pharmaceutical Inc. shifted PKU care to newer options like Palynziq, while generic sapropterin cut pricing power. That mix has kept Kuvan in decline, with management treating it as a non-growth asset. By end-2025, the segment fits a dog profile: weak share, thin economics, and limited reinvestment case.
Aldurazyme, aging MPS I brand
Aldurazyme is a mature MPS I enzyme-replacement therapy for a rare disease affecting about 1 in 100,000 births, so the market stays tiny. Its sales are mainly maintenance, not growth, and the brand’s age limits upside. For BioMarin Pharmaceutical Inc., the commercial case for heavy reinvestment is weak, which fits a Dogs profile.
Legacy non-core collaborations
Legacy non-core collaborations sit in BioMarin Pharmaceutical Inc.'s dog zone: older partnered assets now add little incremental share and get far less capital than core rare-disease drugs. In 2025, BioMarin's growth story stayed centered on newer franchises, while these collaborations remained low-growth and low-priority. That mix usually means weak strategic fit and limited upside.
Slow-moving mature orphan labels
BioMarin Pharmaceutical Inc.’s slow-moving mature orphan labels are steady cash generators, but their demand is flat and far below the growth pace of Voxzogo, which posted over $1.2 billion in 2025 revenue run-rate, while Palynziq kept growing from a much smaller base. That low-growth profile caps strategic value in a BCG Matrix.
- Stable sales, weak expansion
- Limited reinvestment priority
- Lower growth than key stars
High-cost, low-expansion support sales
BioMarin Pharmaceutical Inc.'s mature legacy brands still carry fixed plant, quality, and field-sales costs, so weak volume can keep margins tight. In 2025, this matters most for older enzyme therapies, where flat demand can leave support spend ahead of revenue growth.
- Low growth keeps overhead leverage weak.
- Small volumes still need full support.
- Margin upside needs stronger demand.
That is why these lines fit the Dogs bucket: cash can stay positive, but expansion is limited and cost absorption stays poor.
BioMarin’s Dog Assets: Low Growth, Limited Upside
Kuvan, Aldurazyme, and legacy collaborations sit in BioMarin Pharmaceutical Inc.’s Dogs bucket: low growth, weak share, and limited reinvestment appeal. Kuvan has lost pricing power after generic sapropterin, while Aldurazyme stays in a tiny market near 1 in 100,000 births. BioMarin Pharmaceutical Inc. kept 2025 growth focused on Voxzogo, which topped $1.2 billion in revenue run-rate.
| Asset | 2025 profile | BCG fit |
|---|---|---|
| Kuvan | Generic pressure, declining | Dog |
| Aldurazyme | Mature, tiny market | Dog |
| Legacy collaborations | Low share, low growth | Dog |
Question Marks
Valoctocogene roxaparvovec, severe hemophilia A gene therapy
Valoctocogene roxaparvovec is BioMarin Pharmaceutical Inc.’s biggest swing asset: it won U.S. approval in 2023 for adults with severe hemophilia A, a rare disease seen in about 1 in 5,000 male births. But uptake is still uncertain, so it sits squarely in the Question Mark bucket.
Hemophilia A is a high-value specialty market because severe patients need lifelong bleed control, yet gene therapy only wins if doctors and payers accept its one-time cost and durability. BioMarin needs real share gains from a small base; without that, the asset may stay a costly bet, not a Star.
BMN 307, Phase 1/2 PKU gene therapy
BMN 307 is a Phase 1/2 phenylketonuria gene therapy, so its current market share is 0, but it fits BioMarin Pharmaceutical Inc.’s proven PKU franchise, which generated $2.4 billion in 2024 revenue. If early safety and durability hold, BMN 307 could turn from a question mark into a future star in a market BioMarin already knows well. The main watchpoints are clinical response, safety, and whether it can beat standard PKU treatments.
BMN 255, Phase 1/2 primary hyperoxaluria
BMN 255 is still a Question Mark in BioMarin Pharmaceutical Inc.'s BCG Matrix because it is only in Phase 1/2 for primary hyperoxaluria, an ultra-rare disease with a very small patient pool. Its value is tied to early human proof, since primary hyperoxaluria affects roughly 1 to 3 people per million and even strong efficacy data would still leave a long path to approval and launch. BioMarin's call is simple: if BMN 255 shows clear oxalate reduction and safety in early studies, it can earn a bigger role; if not, the program stays a cash drag.
AAV5 gene therapy platform, no commercial share yet
BioMarin Pharmaceutical Inc.'s AAV gene therapy platform is still a question mark: the science gives it a real shot at a large rare-disease market, but it has not yet built meaningful commercial share. Roctavian, its AAV5-based hemophilia A therapy, showed the platform can reach approval, but uptake has been slow and execution risk remains high.
- Large market, no clear share yet
- AAV5 is an option, not a winner
- Approval proves science; sales must prove scale
Next-generation rare-disease pipeline, early clinical stage
BioMarin's early rare-disease programs are question marks: they can become stars only if they show clear efficacy, safety, and payer demand. With 2024 revenue near $2.4 billion and mature products like Vimizim and Naglazyme already slowing, the company needs fresh launches to replace franchise growth. Until those assets clear late-stage risk, they mainly burn R&D cash and stay optionality, not earnings.
- Early-stage assets still need clinical proof
- Mature franchises need replacement growth
- Capital spend stays high before launch
BioMarin’s Biggest Upside—and Risk—Sits in These Three Assets
BioMarin’s Question Marks are the assets with the most upside and the most risk: Roctavian has U.S. approval but still needs durable sales, while BMN 307 and BMN 255 are early-stage bets with zero market share today. With 2024 revenue near $2.4 billion, BioMarin needs one or more of these programs to prove clinical value and payer demand fast.
| Asset | Status | Why it is a question mark |
|---|---|---|
| Roctavian | Approved | Slow uptake |
| BMN 307 | Phase 1/2 | No share yet |
| BMN 255 | Phase 1/2 | Early proof only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.